Kedudukan dalam Saham
#41692
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-08-11
Perubahan (1 tahun)
-99.76%
Perdagangan Vaxxinity, Inc. (VAXX)
Pendapatan untuk Vaxxinity, Inc. (VAXX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Vaxxinity, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Vaxxinity, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat |
Pendapatan |
Perbezaan Pendapatan |
Negara |
|
|
$5.27B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
$3.01B |
-
|
BE
|
|
|
- |
-
|
KR
|
